On October 30, 2020, Natco Pharma Limited received approval from the FDA for its generic version of the oral drug pomalidomide under ANDA210111, a move that expands the manufacturer's domestic product portfolio and intensifies competition in the immunomodulatory drug market, potentially driving broader price suppression in the treatment of multiple myeloma.